Benitec Biopharma (BNTC) EBIT (2019 - 2025)
Benitec Biopharma (BNTC) posted EBIT of -$13.4 million for Q4 2025, down 36.46% sequentially from -$9.8 million in Q3 2025, and down 23.8% YoY from -$17.6 million in Q4 2024.
Benitec Biopharma (BNTC) EBIT (2019 - 2025) Analysis & Trends
Benitec Biopharma has reported EBIT for 7 years, with the latest figure at -$13.4 million in Q4 2025.
- Quarterly EBIT fell 23.8% year-over-year to -$13.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$48.3 million (down 83.94% YoY) and the FY2025 annual result came in at -$41.8 million, down 85.7% from the prior year.
- EBIT fell to -$13.4 million in Q4 2025 per BNTC's latest filing, from -$9.8 million in the prior quarter.
- Over five years, EBIT peaked at -$3.5 million in Q1 2022 and troughed at -$15.3 million in Q1 2025.
- A 5-year average of -$6.6 million and a median of -$5.2 million in 2021 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2025: EBIT increased 8.78% in 2022, then tumbled 270.32% in 2025.
- Over 5 years, EBIT stood at -$4.8 million in 2021, then decreased by 16.03% to -$5.6 million in 2022, then declined by 23.48% to -$6.9 million in 2023, then tumbled by 55.98% to -$10.8 million in 2024, then slipped by 23.8% to -$13.4 million in 2025.
- According to Business Quant data, EBIT over the past three periods registered -$13.4 million, -$9.8 million, and -$9.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Benitec Biopharma | 577.39 Mn | 388.49 Mn | - | -13.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -13.38 Mn |
| Sep 30, 2025 | -9.80 Mn |
| Jun 30, 2025 | -9.83 Mn |
| Mar 31, 2025 | -15.34 Mn |
| Dec 31, 2024 | -10.81 Mn |
| Sep 30, 2024 | -5.79 Mn |
| Jun 30, 2024 | -5.55 Mn |
| Mar 31, 2024 | -4.14 Mn |
| Dec 31, 2023 | -6.93 Mn |
| Sep 30, 2023 | -5.87 Mn |
| Jun 30, 2023 | -4.55 Mn |
| Mar 31, 2023 | -4.34 Mn |
| Dec 31, 2022 | -5.61 Mn |
| Sep 30, 2022 | -4.58 Mn |
| Jun 30, 2022 | -4.74 Mn |
| Mar 31, 2022 | -3.46 Mn |
| Dec 31, 2021 | -4.84 Mn |
| Sep 30, 2021 | -4.82 Mn |
| Jun 30, 2021 | -3.86 Mn |
| Mar 31, 2021 | -3.79 Mn |